{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:24:09Z","timestamp":1787019849905,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spinal muscular atrophy (SMA) is a chronic, neuromuscular disease characterized by degeneration of spinal cord motor neurons, resulting in progressive muscular atrophy and weakness. SMA1 is the most severe form characterized by significant bulbar, respiratory, and motor dysfunction. SMA1 prevents children from speaking a clearly understandable and fluent language, with their communication being mainly characterized by eye movements, guttural sounds, and anarthria (type 1a); severe dysarthria (type 1b); and nasal voice and dyslalia (type 1c).<\/jats:p>\n                    <jats:p>The aim of this study was to analyze for the first time cognitive functions, language comprehension, and speech in natural history SMA1 children according to age and subtypes, to develop cognitive and language benchmarks that provide outcomes for the clinical medication trials that are changing SMA1 course\/trajectory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective study including 22 children with SMA1 (10 affected by subtype 1a-1b: AB and 12 by 1c: C) aged 3\u201311 years in clinical stable condition with a coded way to communicate \u201cyes\u201d and \u201cno\u201d. Data from the following assessments have been retrieved from patient charts: one-dimensional Raven test (RCPM), to evaluate cognitive development (IQ); ALS Severity Score (ALSSS) to evaluate speech disturbances; Brown Bellugy modified for Italian standards (TCGB) to evaluate language comprehension; and Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) to assess motor functioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SMA 1AB and 1C children were similar in age, with the former characterized by lower CHOP-INTEND scores compared to the latter. All 22 children had collaborated to RCPM and their median IQ was 120 with no difference (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.945) between AB and C. Global median score of the speech domain of the ALSSS was 5; however, it was 2 in AB children, being significantly lower than C (6.5,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                    <jats:p>\n                      TCGB test had been completed by 13 children, with morphosyntactic comprehension being in the normal range (50). Although ALSSS did not correlate with both IQ and TCGB, it had a strong (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) correlation with CHOP-INTEND described by an exponential rise to maximum.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although speech and motor function were severely compromised, children with SMA1 showed general intelligence and language comprehension in the normal range. Speech impairment was strictly related to global motor impairment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s11689-021-09355-4","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T12:13:42Z","timestamp":1612268022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1"],"prefix":"10.1186","volume":"13","author":[{"given":"Grazia","family":"Zappa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"LoMauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mastella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonella","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"issue":"7","key":"9355_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","volume":"25","author":"R Finkel","year":"2015","unstructured":"Finkel R, Bertini E, Muntoni F, Mercuri E. 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk, The Netherlands. Neuromuscul Disord. 2015;25(7):593\u2013602 [cited 2016 Apr 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26045156.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"9355_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315 [cited 2018 Mar 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29290580.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"9355_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197\u2013207 [cited 2018 Mar 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29305137.","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"9355_CR4","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.nmd.2005.07.005","volume":"15","author":"E Bertini","year":"2005","unstructured":"Bertini E, Burghes A, Bushby K, Estournet-Mathiaud B, Finkel RS, Hughes RAC, et al. 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy11\u201313 February 2005Naarden, The Netherlands. Neuromuscul Disord. 2005;15(11):802\u201316.","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"9355_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007 Aug;22(8):1027\u201349.","journal-title":"J Child Neurol"},{"issue":"5","key":"9355_CR6","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Chiarini Testa MB, Mastella C, Rava L, Bignamini E, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131(5):e1509\u201314.","journal-title":"Pediatrics"},{"issue":"2","key":"9355_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11940-009-0012-x","volume":"11","author":"BG Burnett","year":"2009","unstructured":"Burnett BG, Crawford TO, Sumner CJ. Emerging treatment options for spinal muscular atrophy. Curr Treat Options Neurol. 2009;11(2):90\u2013101 [cited 2019 Sep 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19210911.","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"9355_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1399-0004.2009.01200.x","volume":"76","author":"S Rudnik-Sch\u00f6neborn","year":"2009","unstructured":"Rudnik-Sch\u00f6neborn S, Berg C, Zerres K, Betzler C, Grimm T, Eggermann T, et al. Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Clin Genet. 2009;76(2):168\u201378. [cited 2019 Sep 4]. https:\/\/doi.org\/10.1111\/j.1399-0004.2009.01200.x.","journal-title":"Clin Genet"},{"issue":"20","key":"9355_CR9","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","volume":"69","author":"M Oskoui","year":"2007","unstructured":"Oskoui M, Levy G, Garland CJ, Gray JM, O\u2019Hagen J, De Vivo DC, et al. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69(20):1931\u20136 [cited 2019 Sep 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17998484.","journal-title":"Neurology"},{"issue":"11","key":"9355_CR10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Onasemnogene Abeparvovec: First Global Approval. Drugs. 2019;79(11):1255\u201362 [cited 2019 Sep 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31270752.","journal-title":"Drugs"},{"issue":"8","key":"9355_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0000000000006026","volume":"91","author":"BT Darras","year":"2018","unstructured":"Darras BT, De Vivo DC. Precious SMA natural history data. Neurology. 2018;91(8):337\u20139 [cited 2019 Sep 23]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30045956.","journal-title":"Neurology"},{"issue":"11","key":"9355_CR12","doi-asserted-by":"publisher","first-page":"e0165818","DOI":"10.1371\/journal.pone.0165818","volume":"11","author":"A LoMauro","year":"2016","unstructured":"LoMauro A, Aliverti A, Mastella C, Arnoldi MT, Banfi P, Baranello G. Spontaneous breathing pattern as respiratory functional outcome in children with spinal muscular atrophy (SMA). PLoS One. 2016;11(11):e0165818.","journal-title":"PLoS One"},{"issue":"6","key":"9355_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391 [cited 2019 Nov 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29149772.","journal-title":"Ann Neurol"},{"issue":"8","key":"9355_CR14","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1212\/WNL.0000000000006050","volume":"91","author":"M Pane","year":"2018","unstructured":"Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M, et al. An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology. 2018;91(8):e696\u2013703 [cited 2019 Sep 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30045959.","journal-title":"Neurology"},{"issue":"5","key":"9355_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/PHM.0b013e31804a8505","volume":"86","author":"JR Bach","year":"2007","unstructured":"Bach JR, Saltstein K, Sinquee D, Weaver B, Komaroff E. Long-term survival in Werdnig Hoffmann disease. Am J Phys Med Rehabil. 2007;86(5):339\u201345 [cited 2019 Sep 23]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17449977.","journal-title":"Am J Phys Med Rehabil"},{"key":"9355_CR16","doi-asserted-by":"crossref","unstructured":"Ball LJ, Chavez S, Perez G, Bharucha-Goebel D, Smart K, Kundrat K, et al. Communication skills among children with spinal muscular atrophy type 1: a parent survey. Assist Technol. 2019;1\u201311.","DOI":"10.1080\/10400435.2019.1586788"},{"key":"9355_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/mus.20535","volume":"34","author":"MG D\u2019Angelo","year":"2006","unstructured":"D\u2019Angelo MG, Bresolin N. Cognitive impairment in neuromuscular disorders. Muscle Nerve. 2006;34:16\u201333.","journal-title":"Muscle Nerve"},{"issue":"6","key":"9355_CR18","first-page":"550","volume":"81","author":"A Von Gontard","year":"2002","unstructured":"Von Gontard A, Zerres K, Laufersweiler-Plass C, Wendland C, Rudnik-Sch\u00f6neborn S, Lehmkuhl G. Cognitive function and behavioural problems in children and adolescents with spinal muscular atrophy. Am J Med Genet. 2002;81(6):550.","journal-title":"Am J Med Genet"},{"key":"9355_CR19","unstructured":"Hausmanowa-Petrusewicz I. Spinal muscular atrophy \u2013 infantile and juvenile type: Springfield: US Department of Commerce National Technical Information Service; 1978."},{"key":"9355_CR20","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1111\/j.1469-8749.2010.03807.x","volume":"52","author":"J Geytenbeek","year":"2010","unstructured":"Geytenbeek J, Harlaar L, Stam M, Ket H, Becher JG, Oostrom K, et al. Utility of language comprehension tests for unintelligible or non-speaking children with cerebral palsy: a systematic review. Dev Med Child Neurol. 2010;52:e267\u201377.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"9355_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ajmg.b.32224","volume":"165","author":"PF Ajmone","year":"2014","unstructured":"Ajmone PF, Rigamonti C, Dall\u2019Ara F, Monti F, Vizziello P, Milani D, et al. Communication, cognitive development and behavior in children with cornelia de lange syndrome (CdLS): Preliminary results. Am J Med Genet Part B Neuropsychiatr Genet. 2014;165(3):223\u20139.","journal-title":"Am J Med Genet Part B Neuropsychiatr Genet"},{"key":"9355_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13052-015-0110-1","volume":"41","author":"D Milani","year":"2015","unstructured":"Milani D, Manzoni FMP, Pezzani L, Ajmone P, Gervasini C, Menni F, et al. Rubinstein-Taybi syndrome: clinical features, genetic basis, diagnosis, and management. Italian J Pediatr. 2015;41:4.","journal-title":"Italian J Pediatr"},{"issue":"03","key":"9355_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4074\/S0013754510003046","volume":"2010","author":"JM Iverson","year":"2010","unstructured":"Iverson JM. Multimodality in infancy: vocal-motor and speech-gesture coordinations in typical and atypical development. Enfance. 2010;2010(03):257 [cited 2019 Sep 23]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21494413.","journal-title":"Enfance"},{"key":"9355_CR24","first-page":"8","volume":"1","author":"KD Bello","year":"2008","unstructured":"Bello KD, Goharpey N, Crewther SG, Crewther DP. A puzzle form of a non-verbal intelligence test gives significantly higher performance measures in children with severe intellectual disability. BMC Pediatr. 2008;1:8.","journal-title":"BMC Pediatr"},{"key":"9355_CR25","volume-title":"The Standards for Educational and Psychological Testing","author":"AERA, APA, NCME","year":"2014","unstructured":"AERA, APA, NCME. The Standards for Educational and Psychological Testing. 2014."},{"key":"9355_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/joa.12083","volume":"224","author":"M Shababi","year":"2014","unstructured":"Shababi M, Lorson CL, Rudnik-Sch\u00f6neborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anatomy. 2014;224:15\u201328.","journal-title":"J Anatomy"},{"issue":"7","key":"9355_CR27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","volume":"25","author":"R Finkel","year":"2015","unstructured":"Finkel R, Bertini E, Muntoni F, Mercuri E, ENMC SMA Workshop Study Group. 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk, The Netherlands. Neuromuscul Disord. 2015;25(7):593\u2013602 [cited 2019 Nov 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26045156.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"9355_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ridd.2009.09.011","volume":"31","author":"B Facon","year":"2010","unstructured":"Facon B, Nuchadee ML. An item analysis of Raven\u2019s Colored Progressive Matrices among participants with Down syndrome. Res Dev Disabil. 2010;31(1):243\u20139.","journal-title":"Res Dev Disabil"},{"issue":"5","key":"9355_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.intell.2011.04.002","volume":"39","author":"B Facon","year":"2011","unstructured":"Facon B, Magis D, Nuchadee ML, De Boeck P. Do Raven\u2019s Colored Progressive Matrices function in the same way in typical and clinical populations? Insights from the intellectual disability field. Intelligence. 2011;39(5):281\u201391.","journal-title":"Intelligence"},{"key":"9355_CR30","volume-title":"Standardizzazione Italiana","author":"C Belacchi","year":"2008","unstructured":"Belacchi C, Scalisi T, Cannoni E, Cornoldi C. CPM \u2013 Coloured Progressive Matrices. In: Standardizzazione Italiana; 2008."},{"issue":"2","key":"9355_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/07434610801897239","volume":"24","author":"M Larsson","year":"2008","unstructured":"Larsson M, Sandberg AD. Memory ability of children with complex communication needs. Augment Altern Commun. 2008;24(2):139\u201348.","journal-title":"Augment Altern Commun"},{"key":"9355_CR32","volume-title":"TCGB. Test di comprensione grammaticale per bambini. Edizioni del Cerro","author":"A Chilosi","year":"2006","unstructured":"Chilosi A, Cipriani P. TCGB. Test di comprensione grammaticale per bambini. Edizioni del Cerro; 2006."},{"issue":"3","key":"9355_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000110176","volume":"8","author":"AD Hillel","year":"1989","unstructured":"Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiology. 1989;8(3):142\u201350 [cited 2020 Jul 24]. Available from: https:\/\/pubmed-ncbi-nlm-nih-gov.ezproxy.its.uu.se\/2725806\/.","journal-title":"Neuroepidemiology"},{"issue":"3","key":"9355_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, et al. The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability. Neuromuscul Disord. 2010;20(3):155\u201361.","journal-title":"Neuromuscul Disord"},{"key":"9355_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ridd.2016.04.009","volume":"56","author":"J Ballester-Plan\u00e9","year":"2016","unstructured":"Ballester-Plan\u00e9 J, Laporta-Hoyos O, Macaya A, P\u00f3o P, Mel\u00e9ndez-Plumed M, V\u00e1zquez \u00c9, et al. Measuring intellectual ability in cerebral palsy: The comparison of three tests and their neuroimaging correlates. Res Dev Disabil. 2016;56:83\u201398 [cited 2019 May 13]. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891422216300798.","journal-title":"Res Dev Disabil"},{"key":"9355_CR36","volume-title":"Spinal muscular atrophy type I: cases of normal cognitive function despite having limited motor function and physical-environmental interaction","author":"E Leaffer","year":"2015","unstructured":"Leaffer E, Hinton V, Salazar R, Montes J, Dunaway Young S, Holuba LaMarca N, et al. Spinal muscular atrophy type I: cases of normal cognitive function despite having limited motor function and physical-environmental interaction. 2015."},{"issue":"5","key":"9355_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nmd.2017.01.017","volume":"27","author":"GJ Polido","year":"2017","unstructured":"Polido GJ, Barbosa AF, Morimoto CH, Caromano FA, Favero FM, Zanoteli E, et al. Matching pairs difficulty in children with spinal muscular atrophy type I. Neuromuscul Disord. 2017;27(5):419\u201327.","journal-title":"Neuromuscul Disord"},{"issue":"10063","key":"9355_CR38","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u201326.","journal-title":"Lancet"},{"issue":"18","key":"9355_CR39","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1723\u201332 [cited 2019 Sep 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29091570.","journal-title":"N Engl J Med"},{"key":"9355_CR40","doi-asserted-by":"crossref","unstructured":"Meylemans A, De Bleecker J. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review. Acta Neurol. 2019; [cited 2019 Sep 4]; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31388901.","DOI":"10.1007\/s13760-019-01199-z"},{"issue":"6","key":"9355_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11940-019-0568-z","volume":"21","author":"MA Waldrop","year":"2019","unstructured":"Waldrop MA, Kolb SJ. Current treatment options in neurology\u2014SMA therapeutics. Curr Treat Options Neurol. 2019;21(6):25 [cited 2019 Sep 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31037425.","journal-title":"Curr Treat Options Neurol"},{"key":"9355_CR42","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1164\/rccm.201906-1175LE","volume":"200","author":"A LoMauro","year":"2019","unstructured":"LoMauro A, Mastella C, Alberti K, Masson R, Aliverti A, Baranello G. Effect of nusinersen on respiratory muscle function in different subtypes of type 1 spinal muscular atrophy. Am J Respir Crit Care Med. 2019;200:1547\u201350 [cited 2019 Sep 4];Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31433957.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-021-09355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s11689-021-09355-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-021-09355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T12:14:02Z","timestamp":1612268042000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-021-09355-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9355"],"URL":"https:\/\/doi.org\/10.1186\/s11689-021-09355-4","relation":{},"ISSN":["1866-1947","1866-1955"],"issn-type":[{"value":"1866-1947","type":"print"},{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"4 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent for clinical routine assessment and data collection was obtained from parents. The study was approved by the Institutional review board (approval number: 0028609\/11-07_2019bis).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}